A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in Growth Hormone Deficient(GHD) Subjects During the Transition Phase From Childhood to Adulthood

Learn more about:
Related Clinical Trial
Assessment of Adherence, Quality of Life, Clinical Response and Safety of Daily and Long-Acting Growth Hormone Therapy Impact of GH Measurements on GHD Diagnosis Fluids Administration During Combined Clonidine-Arginine Growth Hormone Stimulation Test Three Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the Elderly Free Fatty Acids, Body Weight, and Growth Hormones Secretion in Children A Single Dose Trial in Healthy Caucasians and Japanese Subjects Investigating the Pharmacokinetics of Somatropin Observational Study of Norditropin NordiFlex® With NordiFlex PenMate™ The Impact of the Use of Recombinant Human Growth Hormone on ADHD Characteristics in Children and Adolescents Constructing an Insulin-Like Growth Factor-based Prediction Model Peripheral Metabolic Effects of Somatostatin Chromosome 18 Clinical Research Center The Effect of Dietary Fat Load and Physical Exercise on the Flexibility and Partitioning of Ectopic Lipids. An Observational Study on Treatment Compliance by Children Treated With Growth Hormone A Single Dose Trial in Growth Hormone Deficient Children Investigating Safety, Pharmacokinetics and Pharmacodynamics of Long Acting Growth Hormone A Study to Compare the Uptake Into the Blood of Two Strengths of Somapacitan After Injection Under the Skin in Healthy Subjects Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese Growth Hormone as Add-on Treatment in Severe Fibromyalgia With Low IGF-1 Serum Levels (56 Characters) A Study to Optimize Growth Hormone Dosing in Children With Chronic Kidney Disease by Measuring IGF-1 Levels in Blood Safety and Efficacy of Long-term Somatropin Treatment in Adults Dose Study in Growth Hormone Deficient Adults Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083 r-hGH Liquid Multidose Versus Freeze-dried Multidose Bioequivalence Trial Effects of Growth Hormone and IGF-1 on Anabolic Signals and Stem Cell Recruitment in Human Skeletal Muscle Genotropin Study Assessing Use of Injection Pen Treatment With Recombinant Human Growth Hormone Genotonorm (Registered) In Children With Short Stature Secondary Validation of a Questionnaire That Identifies the Reasons for Non-adherence to Existing Growth Hormone Therapy Treatment of Children With Insufficient Secretion of Growth Hormone Metabolic and QOL Effects of GH Treatment in Patients With TBI and AGHD Anterior Pituitary Hormone Replacement in Traumatic Brain Injury Evolution Of Growth Rate In Children With Growth Retardation Due to Glucocorticosteroid Therapy And Treated By Genotonorm Transition Study: Growth Hormone Therapy In Partial Growth Hormone Deficient Adolescents MOD-4023 (Long-Lasting Human Growth Hormone (hGH)) Study in Growth Hormone Deficient Adults (GHDA) Safety and Efficacy Phase 2 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children Inter-Assay Growth Hormone and IGF-I Variability A Study to Evaluate Growth in Participants Treated With Somatropin (Nutropin) Using NuSpin Device Cardiovascular Risk in Growth Hormone Deficient Young Adult Males After Completing Growth Hormone Therapy Easypod United States User Trial National Cooperative Growth Study in CKD Low and Conventional Dose of Somatropin in Growth Hormone Deficient Adult Patients Practicability and Acceptability of Stylomax® in Children Growth Hormone’s Effect on the Cardiovascular System Exploring Interactions Between Growth Hormone and the Microbiome Pharmacokinetics and Pharmacodynamics of Long Acting Human Growth Hormone (hGH) Product (MOD-4023) in Healthy Caucasian and Japanese Volunteers A Phase 2, Safety and Dose-Finding Study in Treatment-Naive, Pre-Pubertal, Growth Hormone-Deficient Children Phase 1 Safety Study of ALRN-5281 in Healthy Subjects Safety, Pharmacokinetics and Pharmacodynamics Study of HL-032 in Healthy Male Volunteers Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients Growth Hormone and Chromosome 18q- and Abnormal Growth An Observational Study Validating a Score That Quantifies the Therapeutic Response to Treatment With Norditropin® Cross Over Convenience And Preference Study Of New Mark VII Compared To Genotropin Pen In Pediatric And Adult Subjects A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in Growth Hormone Deficient(GHD) Subjects During the Transition Phase From Childhood to Adulthood Study of TV-1106 in Growth Hormone-Deficient Adults Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children Long-Term Efficacy and Safety of Growth Hormone Replacement Therapy in Chronic Heart Failure Crossover Study to Assess the Safety and Pharmacokinetic of Pegylated Somatropin(PEG Somatropin) in GHD Children Study of an Extended-Release, Crystalline Formulation of Recombinant Human Growth Hormone (ALTU-238) in Growth Hormone Deficient Adults to Determine Pharmacokinetics, Pharmacodynamics, and Drug Safety Low Dose Growth Hormone (GH) on Insulin Sensitivity and Cortisol Production Rates Gene Expression in Monocytes of Growth Hormone Deficient Children Study of Pituitary Size and Function in Familial Dwarfism of Sindh Adipocyte Function and Somtropin Deficiency Sustained Release Formulation of Somatropin (rDNA Origin)for Injection Molecular Basis of the Growth Axis in Short Stature Cardiac and Skeletal Muscle Energy Metabolism in Abnormal Growth Hormone States The Effects of Growth Hormone (GH) on Lipid Depots The Effects of TZD on Fat Metabolism and Insulin Sensitivity in GH-Replaced GHD Patients Reference Values for Body Composition Parameters and IGF-I in the Adult NordiNet® International Outcome Study Effects of Growth Hormone Supplementation to Adults With Growth Hormone Deficient on Metabolism and Adipose Tissue Molecular Phenotype Sexually Dimorphic Effects of GHRH in Adult Growth Hormone Testing Metabolic Endocrinology and Growth Hormone in Adults Growth Hormone Treatment of Young Growth Hormone-Deficient Adults Safety and Efficacy of SR-hGH (Sustained-release Human Growth Hormone, Declage Inj.) rhGH Therapy on Hepatic Drug Metabolism Skeletal Muscle Effects of GH in Boys Assessment of Cardiovascular Risk Markers in Growth Hormone Deficient Patients With Nonsecreting Pituitary Adenomas Adipose Tissue and Serum Inflammation in GH Deficiency Adipose Tissue and Circulating Markers of Inflammation in GH Deficiency and Changes With GH Therapy

Brief Title

A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in Growth Hormone Deficient(GHD) Subjects During the Transition Phase From Childhood to Adulthood

Official Title

A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in GHD Subjects During the Transition Phase From Childhood to Adulthood

Brief Summary

      This was a 48-week, open-label, prospective, multicentric, randomised, comparative with
      parallel control, Phase 4 study to evaluate the effects of Saizen on cardiac function in GHD
      subjects during the transition phase from childhood to adulthood.

      The study was designed to evaluate whether recombinant-human growth hormone (r-hGH) treatment
      also benefits young subjects with GHD. Some trials have already been published on this
      subject, but they were mainly focused on the bone density.

Detailed Description

      Growth hormone is a 191 amino acid polypeptide hormone (MW 22,000) normally synthesised and
      secreted by the somatotrophic cells of the anterior lobe of the pituitary gland. In normal
      development, growth hormone and somatomedins are responsible for many of the manifestations
      of normal growth and GHD is manifested by a marked short stature. Growth hormone deficiency
      has been treated by human growth hormone for many years. Serono's r-hGH (Saizen) is produced
      from genetically engineered mammalian cells.

      The findings from previous clinical studies on GH treatment in GH-deficient adults,
      collectively indicate that the majority of adults with long-standing GH deficiency, whether
      dating from childhood or acquired in adult life, are compromised both physically and
      psychologically and can derive clinical benefit from GH replacement. Based on observations in
      the clinical trials to date , a GH dose of 0.01 mg/kg/day (50% of the dose used in children),
      is likely to be satisfactory for many subjects. Moreover, it should be possible to minimise
      early side effects, particularly fluid retention, by initiating treatment with half of this
      dose and increasing to the final dose after 4 weeks if well tolerated.

      In this study, it was proposed to enroll a group of childhood onset GHD subjects who were not
      treated with r-hGH. Half of the study population started treatment for six months whilst the
      other half remained on no r-hGH treatment. After six months the group already on r-hGH
      therapy continued treatment for a further six months and the second group presently on no
      r-hGH treatment started r hGH treatment for the remaining six months of the study.


      Primary objective:

        -  To compare the effects of Saizen on cardiac function (as assessed by percentage ejection
           fraction) in subjects where 50% of the study population started r-hGH treatment for 24
           weeks and then remained on r-hGH treatment for a further 24 weeks and subjects who
           continued on no r-hGH for 24 weeks before starting r-hGH for 24 weeks during the
           transition phase from childhood to adulthood.

      Secondary objectives:

      - To assess the safety and tolerability of r-hGH in subjects who were transitioning from
      childhood to adulthood, and to assess the change in body composition and lean body mass.
      Subsidiary analyses of the other echocardiography parameters was also performed.

      After entry into the trial, the subjects were randomised to one of two groups for a 48-week

        -  Group 1: Saizen (r-hGH), 0.15-1.00 mg/day for 48 weeks, subcutaneous (s.c.)

        -  Group 2: No treatment for the first 24 weeks followed by Saizen (r-hGH)0.15-1.00 mg/day
           for the next 24 weeks, s.c.

      Subjects' visits to the study site was scheduled as follows:

        -  Group 1 - Baseline (study day 1), weeks 4, 12, 24, 36 & 48.

        -  Group 2 - Baseline (study day 1), weeks 12, 24, 28, 36 & 48. The study drug was
           administered subcutaneously once daily in the evenings during the active treatment
           period. The dose was to be adjusted stepwise, controlled by Insulin-Growth Factor-I
           (IGF-I) values. The recommended final r-hGH dose was not to exceed 1.00mg/day

Study Phase

Phase 4

Study Type


Primary Outcome

Change in percentage ejection fraction in subjects during the transition phase from childhood to adulthood

Secondary Outcome

 Subsidiary analysis of the other echocardiography parameters and lean body mass





Study Arms / Comparison Groups

 Group 1


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

September 2003

Completion Date

February 2005

Primary Completion Date

February 2005

Eligibility Criteria

        Inclusion Criteria:

          -  Subjects with diagnosis of childhood onset GH deficiency and previously treated with

          -  Subjects who had attained final height

          -  Male or female subjects, aged between 14 and 25 years of age inclusively at baseline

          -  Subjects with GH deficiency of <5μg/L (acquired or idiopathic), established by any 1
             type of GH secretion test within 3 years prior to Study Day 1

          -  If hypopituitary, subject must have been on adequate replacement therapy (if required)
             of glucocorticosteroids, thyroid & sex hormones (hormones levels on replacement being
             in normal/mildly elevated range) for at least 6 months prior to study entry

          -  Subjects who were willing and able to comply with the protocol for the duration of the

          -  Subjects who had given written informed consent before any study-related procedure not
             part of the subject's normal medical care, with the understanding that the subject
             might withdraw consent at any time without prejudice to future medical care

          -  Female subjects must be neither pregnant nor breast-feeding, and use a hormonal
             contraceptive, intra-uterine device, diaphragm with spermicide or condom with
             spermicide for the duration of the study. Confirmation that a female subject was not
             pregnant was established by a negative urinary human chorionic gonadotropin (hCG)
             pregnancy test at baseline.

        Exclusion Criteria:

          -  Subject who had a known allergy or hypersensitivity to growth hormone or diluent

          -  Subject who had been treated with r-hGH in previous six months

          -  Subject with chronic severe kidney disease

          -  Subject with chronic severe liver disease

          -  Subject with acute or severe illness during the previous 6 months

          -  Subject with significant concomitant illness which would interfere with his/her
             participation or assessment in this study

          -  Subject with active malignancy (except non-melanomatous skin malignancies)

          -  Subjects with unstable hypertension (supine systolic blood pressure persistently above
             160 mmHg or diastolic blood pressure persistently above 100 mmHg)

          -  Subjects with benign cranial hypertension

          -  Subjects with a history of carpal tunnel syndrome, unless surgically released

          -  Subjects with known positive human immunodeficiency virus (HIV), Hepatitis B surface
             antigen (HBsAg) and/or Hepatitis C virus (HCV) serology based on past medical history

          -  Subjects with known active drug addiction, including alcoholism, or use of drugs for
             nontherapeutic purposes

          -  Subject who had previously participated in this study

          -  Subject taking an investigational drug or enrolled in another clinical study




14 Years - 25 Years

Accepts Healthy Volunteers



Theodor Wee, MD, , 

Administrative Informations



Organization ID


Study Sponsor

Merck KGaA, Darmstadt, Germany

Study Sponsor

Theodor Wee, MD, Study Director, Merck Serono International SA

Verification Date

July 2010